Cidara Therapeutics, Inc.
CDTX
$220.98
$1.090.50%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -100.00% | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -100.00% | -- |
| Cost of Revenue | 185.86% | 272.80% | 315.61% | 485.19% | 19.67% |
| Gross Profit | -185.86% | -290.51% | -397.37% | -792.16% | -963.22% |
| SG&A Expenses | 63.12% | 37.00% | 71.83% | 112.01% | 50.50% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 150.82% | 174.66% | 165.57% | 372.92% | 27.10% |
| Operating Income | -150.82% | -182.13% | -195.82% | -522.71% | -289.30% |
| Income Before Tax | -435.78% | 72.70% | -187.15% | -540.68% | -302.98% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -435.78% | 72.70% | -187.15% | -540.13% | -306.36% |
| Earnings from Discontinued Operations | -- | -- | -- | -98.75% | 91.48% |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -420.69% | 71.80% | -127.39% | -1,527.98% | -75.52% |
| EBIT | -150.82% | -182.13% | -195.82% | -522.71% | -289.30% |
| EBITDA | -151.25% | -182.83% | -196.65% | -524.62% | -290.31% |
| EPS Basic | -26.48% | 91.72% | 27.22% | -657.34% | -21.35% |
| Normalized Basic EPS | 40.22% | 6.68% | 8.09% | -198.05% | -178.60% |
| EPS Diluted | -26.48% | 91.73% | 27.22% | -655.13% | -21.15% |
| Normalized Diluted EPS | 40.22% | 6.68% | 8.09% | -198.05% | -178.60% |
| Average Basic Shares Outstanding | 311.67% | 240.67% | 212.44% | 114.97% | 44.65% |
| Average Diluted Shares Outstanding | 311.67% | 240.67% | 212.44% | 114.97% | 44.65% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |